A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.
An existing body of literature shows that marital status and related social support are connected with disease outcomes.
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma.
A nested case-control study found that the association between obesity and RCC varies depending on subtype.
TURBT with fluorescent light source using oral 5-ALA is well tolerated in non–muscle-invasive bladder cancer.
Patients with muscle-invasive bladder cancer who underwent trimodal therapy had significantly poorer survival than those who underwent radical cystectomy alone.
The statement emphasizes strategies for multidisciplinary care, and proposes an algorithm for clinical management of bone metastasis in RCC.
PFS, tumor response, and safety outcomes were similar in patient cohorts under age 75 vs those 75 years of age and older.
More than 20% of patients with non–clear cell RCC had a germline mutation, and half of this group could benefit from direct systemic therapy.
A new study identified several metabolites and metabolic indicators as potential biomarkers for recurrence risk in non–muscle-invasive bladder cancer.